vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $194.8M, roughly 1.3× TOMPKINS FINANCIAL CORP). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs 11.1%, a 38.3% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 29.6%). TOMPKINS FINANCIAL CORP produced more free cash flow last quarter ($31.9M vs $29.1M). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
ANIP vs TMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $194.8M |
| Net Profit | $27.5M | $96.2M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 71.7% |
| Net Margin | 11.1% | 49.4% |
| Revenue YoY | 29.6% | 152.7% |
| Net Profit YoY | 367.5% | 388.9% |
| EPS (diluted) | $1.14 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $194.8M | ||
| Q3 25 | $227.8M | $87.4M | ||
| Q2 25 | $211.4M | $82.6M | ||
| Q1 25 | $197.1M | $81.7M | ||
| Q4 24 | $190.6M | $77.1M | ||
| Q3 24 | $148.3M | $76.6M | ||
| Q2 24 | $138.0M | $72.7M | ||
| Q1 24 | $137.4M | $72.8M |
| Q4 25 | $27.5M | $96.2M | ||
| Q3 25 | $26.6M | $23.7M | ||
| Q2 25 | $8.5M | $21.5M | ||
| Q1 25 | $15.7M | $19.7M | ||
| Q4 24 | $-10.3M | $19.7M | ||
| Q3 24 | $-24.2M | $18.6M | ||
| Q2 24 | $-2.3M | $15.7M | ||
| Q1 24 | $18.2M | $16.9M |
| Q4 25 | 14.1% | 71.7% | ||
| Q3 25 | 15.9% | 35.6% | ||
| Q2 25 | 6.6% | 34.2% | ||
| Q1 25 | 13.3% | 31.6% | ||
| Q4 24 | -2.3% | 33.4% | ||
| Q3 24 | -13.8% | 32.0% | ||
| Q2 24 | 3.7% | 28.3% | ||
| Q1 24 | 14.8% | 30.4% |
| Q4 25 | 11.1% | 49.4% | ||
| Q3 25 | 11.7% | 27.1% | ||
| Q2 25 | 4.0% | 26.0% | ||
| Q1 25 | 8.0% | 24.1% | ||
| Q4 24 | -5.4% | 25.5% | ||
| Q3 24 | -16.3% | 24.3% | ||
| Q2 24 | -1.7% | 21.6% | ||
| Q1 24 | 13.2% | 23.2% |
| Q4 25 | $1.14 | $6.72 | ||
| Q3 25 | $1.13 | $1.65 | ||
| Q2 25 | $0.36 | $1.50 | ||
| Q1 25 | $0.69 | $1.37 | ||
| Q4 24 | $-0.45 | $1.39 | ||
| Q3 24 | $-1.27 | $1.30 | ||
| Q2 24 | $-0.14 | $1.10 | ||
| Q1 24 | $0.82 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $132.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $938.4M |
| Total Assets | $1.4B | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $132.8M | ||
| Q3 25 | $262.6M | $193.5M | ||
| Q2 25 | $217.8M | $212.6M | ||
| Q1 25 | $149.8M | $193.1M | ||
| Q4 24 | $144.9M | $134.4M | ||
| Q3 24 | $145.0M | $132.3M | ||
| Q2 24 | $240.1M | $70.9M | ||
| Q1 24 | $228.6M | $57.1M |
| Q4 25 | $540.7M | $938.4M | ||
| Q3 25 | $505.8M | $788.8M | ||
| Q2 25 | $436.8M | $761.8M | ||
| Q1 25 | $418.6M | $741.4M | ||
| Q4 24 | $403.7M | $713.4M | ||
| Q3 24 | $405.9M | $719.9M | ||
| Q2 24 | $455.8M | $674.6M | ||
| Q1 24 | $452.0M | $667.9M |
| Q4 25 | $1.4B | $8.7B | ||
| Q3 25 | $1.4B | $8.5B | ||
| Q2 25 | $1.3B | $8.4B | ||
| Q1 25 | $1.3B | $8.2B | ||
| Q4 24 | $1.3B | $8.1B | ||
| Q3 24 | $1.3B | $8.0B | ||
| Q2 24 | $920.8M | $7.9B | ||
| Q1 24 | $914.5M | $7.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $38.9M |
| Free Cash FlowOCF − Capex | $29.1M | $31.9M |
| FCF MarginFCF / Revenue | 11.8% | 16.4% |
| Capex IntensityCapex / Revenue | 0.5% | 3.6% |
| Cash ConversionOCF / Net Profit | 1.10× | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $38.9M | ||
| Q3 25 | $44.1M | $34.9M | ||
| Q2 25 | $75.8M | $18.9M | ||
| Q1 25 | $35.0M | $22.2M | ||
| Q4 24 | $15.9M | $95.0M | ||
| Q3 24 | $12.5M | $21.2M | ||
| Q2 24 | $17.4M | $27.3M | ||
| Q1 24 | $18.3M | $23.2M |
| Q4 25 | $29.1M | $31.9M | ||
| Q3 25 | $38.0M | $33.9M | ||
| Q2 25 | $71.8M | $18.3M | ||
| Q1 25 | $32.5M | $20.9M | ||
| Q4 24 | $13.5M | $88.8M | ||
| Q3 24 | $7.7M | $18.9M | ||
| Q2 24 | $13.0M | $26.3M | ||
| Q1 24 | $13.7M | $21.9M |
| Q4 25 | 11.8% | 16.4% | ||
| Q3 25 | 16.7% | 38.8% | ||
| Q2 25 | 34.0% | 22.1% | ||
| Q1 25 | 16.5% | 25.5% | ||
| Q4 24 | 7.1% | 115.1% | ||
| Q3 24 | 5.2% | 24.7% | ||
| Q2 24 | 9.4% | 36.2% | ||
| Q1 24 | 10.0% | 30.0% |
| Q4 25 | 0.5% | 3.6% | ||
| Q3 25 | 2.7% | 1.1% | ||
| Q2 25 | 1.9% | 0.8% | ||
| Q1 25 | 1.3% | 1.7% | ||
| Q4 24 | 1.3% | 8.1% | ||
| Q3 24 | 3.2% | 2.9% | ||
| Q2 24 | 3.2% | 1.3% | ||
| Q1 24 | 3.3% | 1.9% |
| Q4 25 | 1.10× | 0.40× | ||
| Q3 25 | 1.66× | 1.47× | ||
| Q2 25 | 8.87× | 0.88× | ||
| Q1 25 | 2.23× | 1.13× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.74× | ||
| Q1 24 | 1.00× | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TMP
Segment breakdown not available.
